All In Biotech

Drug Trial Radar · NCT02594124

A Study for Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in Nusinersen (ISIS 396443) Investigational Studies

An Open-Label Extension Study for Patients With Spinal Muscular Atrophy Who Previously Participated in Investigational Studies of ISIS 396443

Last checked: Nov 20, 2026Latest source record: Oct 22, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

292

Actual

Start

Nov 4, 2015

Primary completion

Aug 21, 2023

Study completion Aug 21, 2023

Sponsor

Lead sponsor
BiogenBiogen (BIIB)
Sponsor type
Industry
First posted
Nov 2, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective is to evaluate long-term safety and tolerability of nusinersen (ISIS 396443) administered by intrathecal (IT) injection to participants with Spinal Muscular Atrophy (SMA) who previously participated in investigational studies of nusinersen. The secondary objective is to examine the long-term efficacy of nusinersen administered by IT injection to participants with SMA who previously participated in investigational studies of nusinersen.

Conditions

  • Spinal Muscular Atrophy

Interventions

  • nusinersenDrug

    Administered by intrathecal (IT) injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: From Day 1 up to the end of the study (up to 2848 days)
  2. Number of Participants With Vital Sign Abnormalities Reported as AEsTime frame: From Day 1 up to the end of the study (up to 2848 days)
  3. Number of Participants With Weight Abnormalities Reported as AEsTime frame: From Day 1 up to the end of the study (up to 2848 days)
  4. Number of Participants With Neurological Abnormalities Reported as AEsTime frame: From Day 1 up to the end of the study (up to 2848 days)
  5. Number of Participants With Laboratory Abnormalities Reported as AEsTime frame: From Day 1 up to the end of the study (up to 2848 days)
  6. Number of Participants With Coagulation Parameters Reported as AEsTime frame: From Day 1 up to the end of the study (up to 2848 days)
  7. Number of Participants With Clinically Significant Shifts in12 Lead Electrocardiogram (ECG) ResultsTime frame: From Day 1 up to the end of the study (up to 2848 days)
  8. Number of Participants Taking Any Concomitant MedicationTime frame: From Day 1 up to the end of the study (up to 2848 days)

Locations

47 sites in 14 countries. Site status is shown where the registry gives one.

  • David Geffen School of Medicine at UCLA

    Los Angeles, California

  • Stanford University School of Medicine

    Palo Alto, California

  • Children's Hospital Colorado

    Aurora, Colorado

  • Connecticut Children's Medical Center

    Hartford, Connecticut

  • Nemours Children's Clinic

    Orlando, Florida

  • Ann & Robert H. Lurie Children's Hospital of Chicago

    New York, Illinois

  • The Johns Hopkins Hospital

    Baltimore, Maryland

  • Boston Children's Hospital

    Boston, Massachusetts

  • Gillette Children's Specialty Healthcare

    Saint Paul, Minnesota

  • Washington University School of Medicine

    St Louis, Missouri

  • Columbia University Medical Center

    New York, New York

  • Duke University School of Medicine

    Durham, North Carolina

  • Duke University School of Medicine

    Miyagi, North Carolina

  • Oregon Health Sciences University

    Durham, Oregon

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania

  • Children's Medical Center

    Dallas, Texas

  • University of Utah

    Obu, Aichi, Utah

  • Seattle Children's Hospital

    Seattle, Washington

  • Sydney Children's Hospital Clinical Research Centre

    Sydney, New South Wales, Australia

  • Royal Children's Hospital

    Parkville, Victoria, Australia

  • Universitair Kinderziekenhuis Koningin Fabiola

    Brussels, Belgium

  • BC Children's Hospital / UBC

    Vancouver, British Columbia, Canada

  • Children's Health Research Institute

    Brussel, Ontario, Canada

  • McGill University Health Centre

    Montreal, Quebec, Canada

  • Armand Trousseau Hospital, I-Motion

    Paris, Paris 9, France

  • Universitatsklinikum Essen

    Essen, Germany

  • Universitaetsklinikum Freiburg

    Freiburg im Breisgau, Germany

  • LMU-Campus Innenstadt

    Munich, Bavaria, Germany

  • The University of Hong Kong

    Hong Kong, Hong Kong SAR, Hong Kong

  • Pediatric Neurology Unit, Catholic University

    Essen, Italy

  • Istituto Giannina Gaslini, Centro Traslazionale di Miologia

    Genova, Italy

  • Department of Neuroscience, Università di Messina, AOU Polic

    Messina, Italy

  • Kumamoto University Hospital

    Kumamoto, Japan

  • Miyagi Prefectural Children Hospital

    Miyagi, Japan

  • University of Miyazaki Hospital

    Miyazaki, Japan

  • Aichi Children's Health and Medical Center

    Ōbu, Aichi-ken, Japan

  • Hyogo College of Medicine

    Nishinomiya, Hyōgo, Japan

  • Tokyo Women's Medical University

    Shinjuku-ku, Tokyo, Japan

  • Seoul National University Hospital

    Seoul, Korea, South Korea

  • Hospital Sant Joan de Deu

    Barcelona, Spain

Showing 40 of 47 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.